A New Class of 1‐Aryl‐5,6‐dihydropyrrolo[2,1‐
<i>a</i>
]isoquinoline Derivatives as Reversers of P‐Glycoprotein‐Mediated Multidrug Resistance in Tumor Cells
作者:Alisa A. Nevskaya、Maria D. Matveeva、Tatiana N. Borisova、Mauro Niso、Nicola A. Colabufo、Angelina Boccarelli、Rosa Purgatorio、Modesto de Candia、Saverio Cellamare、Leonid G. Voskressensky、Cosimo D. Altomare
DOI:10.1002/cmdc.201800177
日期:2018.8.10
an‐2‐yl)‐5,6‐dihydropyrrolo[2,1‐a]isoquinoline‐2‐carbaldehyde, attained sub‐micromolar inhibitory potency (IC50: 0.19 μm). Schiff bases prepared by the condensation of some 1‐aryl‐DHPIQ aldehydes with p‐aminophenol also proved to be of some interest, and one of them, 4‐((1‐(4‐fluorophenyl)‐5,6‐dihydro‐8,9‐dimethoxypyrrolo[2,1‐a]isoquinolin‐2‐yl)methyleneamino)phenol, had an IC50 value of 1.01 μm. In
合成了许多与lamellarin生物碱家族成员共享5,6-二氢吡咯并[ 2,1 - a ]异喹啉(DHPIQ)支架的氮杂杂环化合物,并评估了它们逆转体外多药耐药性的能力。通过抑制P-糖蛋白(P-gp)和/或多药耐药相关蛋白来抑制癌细胞1.大多数研究的DHPIQ化合物被证明是选择性P-gp调节剂,而最有效的调节剂8,9-二乙氧基-1-(3,4-二乙氧基苯基)-3-(呋喃-2-基)-5,6-二氢吡咯并[ 2,1- a ]异喹啉-2-甲醛,达到亚微摩尔抑制力(IC 50:0.19 μ米)。通过一些1-芳基-DHPIQ醛与p缩合制备的席夫碱氨基苯酚也被证明是令人感兴趣的,其中之一是4-(((1-(4-氟苯基))5,6-二氢-8,9-二甲氧基吡咯并[ 2,1- a ]异喹啉-2-基)亚甲基氨基)苯酚,有一个IC 50为1.01μ值米。在多药耐药细胞的药物联合测定中,一些DHPIQ化合物以无毒浓度显着